A novel therapy for atopic dermatitis (AD) led to at least 75% improvement in a third of patients after 6 months, a ...

All the key secondary endpoints of the trial were met, demonstrating the “statistical significance” of the therapy.

In September 2024, a readout from a separate trial of rocatinlimab elicited mixed reactions from analysts, who found the ...

Amgen’s $400 million eczema drug candidate has recorded two more phase 3 victories. The data drops provide more evidence that ...

Amgen and Kyowa Kirin's rocatinlimab showed strong efficacy in Phase 3 trials for atopic dermatitis, achieving key endpoints ...

Data from two more late-stage studies show that treatment with Amgen's rocatinlimab improves outcomes in atopic dermatitis indication.

Term Maintenance and Durability THOUSAND OAKS, Calif., and TOKYO, March 8, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and Kyowa Kirin Co., Ltd. (Kyowa ...

US biotech Amgen (Nasdaq: AMGN) and Japanese partner Kyowa Kirin (TYO: 4151) announced new results from the ongoing ROCKET ...

Sapiens International Corporation , a leading global provider of software solutions for the insurance industry, announced ...

Piper Sandler analyst David Amsellem reiterated a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $329.00. The ...

Shawn Kwatra, MD, FAAD, physician scientist at the University of Maryland Medical System, presented data at the American Academy of Dermatology 2025 annual conference on the rapid efficacy of topical ...

Abrocitinib was efficacious and safe in patients with atopic dermatitis who did and who did not respond to prior treatment with dupilumab.